An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.
about
AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomasGuidance of Signaling Activations by Cadherins and Integrins in Epithelial Ovarian Cancer CellsThe IL-8/IL-8R Axis: A Double Agent in Tumor Immune ResistanceThe role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancerHypoxic control of metastasisBiomarkers for the early diagnosis of hepatocellular carcinomaMultiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic TargetsIs there a role for epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor wild-type non-small cell lung cancer?Cancer Cell Line Panels Empower Genomics-Based Discovery of Precision Cancer MedicinePredictive biomarkers in precision medicine and drug development against lung cancerMicroRNA regulation of tumorigenesis, cancer progression and interpatient heterogeneity: towards clinical useAXL kinase as a novel target for cancer therapyTargeted therapies in development for non-small cell lung cancerSignaling cross-talk in the resistance to HER family receptor targeted therapyActivation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung CancerCo-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.A perspective on anti-EGFR therapies targeting triple-negative breast cancerMolecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to TherapyImplications of Hypoxia in Breast Cancer Metastasis to BoneComprehensive genomic characterization of head and neck squamous cell carcinomasLung Cancer Gene Signatures and Clinical PerspectivesThe miR-200 family and the miR-183~96~182 cluster target Foxf2 to inhibit invasion and metastasis in lung cancers.In-depth analysis shows synergy between erlotinib and miR-34aEnsemble-based network aggregation improves the accuracy of gene network reconstructionParadoxical role of the proto-oncogene Axl and Mer receptor tyrosine kinases in colon cancerA genome-scale screen reveals context-dependent ovarian cancer sensitivity to miRNA overexpressionSMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancersComprehensive evaluation of published gene expression prognostic signatures for biomarker-based lung cancer clinical studies.Correlating chemical sensitivity and basal gene expression reveals mechanism of action.Epigenetic coordination of signaling pathways during the epithelial-mesenchymal transitionA rapid in vivo screen for pancreatic ductal adenocarcinoma therapeutics.ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism.Molecular pathways and therapeutic targets in lung cancerClinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell linesNullifying the CDKN2AB locus promotes mutant K-ras lung tumorigenesis.miR-200c-driven Mesenchymal-To-Epithelial Transition is a Therapeutic Target in Uterine Carcinosarcomas.New insights into the role of EMT in tumor immune escape.Characterization of Human Cancer Cell Lines by Reverse-phase Protein ArraysActivation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy.
P2860
Q24336818-C0047E5A-CAFB-4E76-BB9B-34B0A8BECA3FQ26738643-1DCEBD32-0976-47EB-91AA-18C1D88485B1Q26746986-E366C859-E74B-4BF2-852B-0EC2E1C63F37Q26749110-3CD79EA7-B34E-4EE0-94AC-4DE7E51B7454Q26749159-3C9D9CE7-2027-4E06-B786-39FE78B316A5Q26784418-9A11D8AD-C279-41A2-9A61-4A0DDCCD94D7Q26795735-4E450170-83E2-48F5-843D-C82AA05E8375Q26798882-FF59F0C6-012E-45B5-A704-81CB1878536FQ26800337-898B08BD-5F39-412F-9F6B-042C3FB73923Q26824536-907B952C-3354-4DBA-95C7-D636F54B30E3Q26861185-1A98D479-B503-428D-8AF1-51710EEC23CEQ26863442-F601F31A-9F56-4112-88EF-870DA6886B42Q27022852-A895B401-29E8-4137-8B4E-82C1B59CCFC3Q27027778-2FC61D1A-223B-4650-BB04-ABC19860CFBDQ27315948-C894FED7-9D9C-46B8-9E7F-96FCACC3F946Q27345462-1C3705B6-269A-4244-8D63-403779B58A36Q27852553-214F4703-FB39-485A-BF35-C502A11A1E18Q28069867-27A13A9C-FAA7-4EEB-A490-899EA5066594Q28070028-4A0D6C49-E011-4767-978D-DC9B1CB5CC0EQ28077444-97D2924F-7783-48AD-89FC-4B984FAF66CCQ28256121-CDE02FB6-A0FB-4445-B727-E76C5CC795C3Q28387769-68DF9276-8709-460B-B840-F2B0473A1622Q28389376-117E5399-9E9E-4E9B-A93A-7BD6806C2008Q28539851-08A0C103-993B-4E79-8AA9-F54D2D14DD35Q28544882-248CC32B-1B25-46B3-BCF0-4E1C90AC4CECQ28588141-4344931F-0E50-42A4-A392-6309C0CF0EE4Q28611264-94CC6ACA-525D-4A84-BD33-7222DEA91EC4Q28818608-7FCB1A8F-CE9B-49A9-82FD-2FDBE8006ED1Q30235944-14681A5D-82E0-43D2-859E-F4A76AEE0561Q30381469-DAA7D1A6-6007-4092-8A56-F54B89F5D6A2Q30415888-C8EC6899-A019-472D-B1C1-EDFD38744B84Q30669159-1B625B3B-55A8-4869-AFFC-550960FA587DQ33685931-750B3FA6-049C-4A24-B3BD-53277991F847Q33688872-F0B46E0D-3C82-4E71-9E73-1004EA0C63DDQ33742964-E23881EB-2273-4E1F-8E35-BAE91DA5F7E8Q33758232-586B9CB2-9504-4DA2-BB72-B38AFCDFD74EQ33804175-4BC0C901-47AE-4265-A603-E5BDD72DDA40Q33869781-F67B4423-8F90-4310-AD1C-81B9D7C0CC23Q33882864-51B5043F-2EA6-4CD1-8ED4-3BB95C765B37Q33891230-2D55B21A-DB7A-41A8-83A0-D688845ADA09
P2860
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
An epithelial-mesenchymal tran ...... ing EGFR inhibitor resistance.
@ast
An epithelial-mesenchymal tran ...... ing EGFR inhibitor resistance.
@en
type
label
An epithelial-mesenchymal tran ...... ing EGFR inhibitor resistance.
@ast
An epithelial-mesenchymal tran ...... ing EGFR inhibitor resistance.
@en
prefLabel
An epithelial-mesenchymal tran ...... ing EGFR inhibitor resistance.
@ast
An epithelial-mesenchymal tran ...... ing EGFR inhibitor resistance.
@en
P2093
P2860
P50
P1476
An epithelial-mesenchymal tran ...... ing EGFR inhibitor resistance.
@en
P2093
Edward S Kim
Gordon B Mills
J Jack Lee
Jason M Foulks
Jayanthi Gudikote
John D Minna
John N Weinstein
K Kian Ang
P2860
P304
P356
10.1158/1078-0432.CCR-12-1558
P407
P577
2012-10-22T00:00:00Z